Fenwick & West represented Sierra Oncology, Inc. (NAS: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, in its public offering of 19,500,000 shares of its common stock at a price of $1.35 per share with gross proceeds of approximately $26.3 million. The offering was made pursuant to an effective shelf registration statement previously filed with the SEC. As part of the offering, Sierra Oncology, Inc. granted the underwriters an option for a period of 30 days to purchase up to an additional 2,925,000 shares of common stock at the public offering price.
Jefferies LLC acted as the sole book-running manager for the offering. Wedbush PacGrow and SunTrust Robinson Humphrey, Inc. acted as co-managers.
The Fenwick transaction team included corporate partners Stephen Graham and Robert Freedman and associates Amanda Rose and Christopher Walton.